- Home
- ADVB vs KPRX Comparison
ADVB vs KPRX Comparison
Compare ADVB & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVB
- KPRX
- Stock Information
- Founded
- ADVB 2014
- KPRX 1998
- Country
- ADVB United States
- KPRX United States
- Employees
- ADVB N/A
- KPRX N/A
- Industry
- ADVB Medical Specialities
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ADVB Health Care
- KPRX Health Care
- Exchange
- ADVB Nasdaq
- KPRX Nasdaq
- Market Cap
- ADVB 9.1M
- KPRX 9.2M
- IPO Year
- ADVB 2025
- KPRX N/A
- Fundamental
- Price
- ADVB $0.56
- KPRX $2.65
- Analyst Decision
- ADVB
- KPRX Strong Buy
- Analyst Count
- ADVB 0
- KPRX 1
- Target Price
- ADVB N/A
- KPRX $10.00
- AVG Volume (30 Days)
- ADVB 373.8K
- KPRX 26.7K
- Earning Date
- ADVB 11-03-2025
- KPRX 11-07-2025
- Dividend Yield
- ADVB N/A
- KPRX N/A
- EPS Growth
- ADVB N/A
- KPRX N/A
- EPS
- ADVB N/A
- KPRX N/A
- Revenue
- ADVB N/A
- KPRX N/A
- Revenue This Year
- ADVB N/A
- KPRX N/A
- Revenue Next Year
- ADVB N/A
- KPRX N/A
- P/E Ratio
- ADVB N/A
- KPRX N/A
- Revenue Growth
- ADVB N/A
- KPRX N/A
- 52 Week Low
- ADVB $0.34
- KPRX $2.25
- 52 Week High
- ADVB $4.10
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- ADVB N/A
- KPRX 46.53
- Support Level
- ADVB N/A
- KPRX $2.58
- Resistance Level
- ADVB N/A
- KPRX $2.80
- Average True Range (ATR)
- ADVB 0.00
- KPRX 0.11
- MACD
- ADVB 0.00
- KPRX -0.01
- Stochastic Oscillator
- ADVB 0.00
- KPRX 21.88
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.